Good MorningEquity markets started Tuesday's session on an uncertain footing after tensions in Ukraine escalated. However, the market quickly regained footing to confirm support at a critical level, aligning with the election-inspired rally two weeks ago. With this in play, the odds are high that the election-driven rally is not over and that the S&P 500 index will soon set a new high.
Results from Walmart aided the market rebound. The world's largest employer outpaced consensus on the top and bottom lines and raised its guidance, citing resilient consumer health and steady spending. The news suggests the holiday shopping season will be merry and bright, lifting Walmart's stock price by 5% to set a new all-time high. Analysts are lifting their targets for WMT stock, which may continue to trend higher through the end of the year. Featured: How to Collect Up To $5,917/mo From Trump’s Made In USA Boom (Ad) 
|
Stocks | | | U.S. stocks climbed Thursday after market superstar Nvidia and another round of companies said they’re making even fatter profits than expected.The S&P 500 pulled 0.5% higher after flipping between gains and losses several times during the day. Banks, smaller companies and other areas of the st... Read the Full Story |
|
From Our Partners | | Leaked: Jobs’ Final Apple Project Exposed
Bloomberg just leaked details of a secret project Steve Jobs set in motion before his death. After more than a decade under wraps, Apple is finally preparing to unleash this breakthrough — one that could reshape a $9 trillion industry overnight. | | Its secret codename… Project Mulberry. |
|
Markets | | | In an industry often characterized by high growth rather than dividend income, finding semiconductor companies that offer both can be particularly appealing. Below are three semiconductor stocks that provide investors with dividend payouts and have recently announced notable increases. I’ll re... Read the Full Story |
|
Markets | | |
For conservative investors seeking steady income and long-term growth, dividend ETFs offer a reliable "buy and hold" strategy. These funds provide diversification, consistent payouts, and the ease of passive management, making them ideal for a stable, hands-off portfolio. With careful selection, d... Read the Full Story |
|
From Our Partners | | I made a mistake.
A mistake I feel very foolish about.
After speaking with Donald Trump and some of his advisors, I believed him.
I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years.
But I was wrong. | | Let me show you exactly what we’re doing to prepare. |
|
Markets | | | Nvidia on Wednesday reported a surge in third-quarter profit and sales as demand for its specialized computer chips that power artificial intelligence systems remains robust.For the three months that ended Oct. 27, the tech giant based in Santa Clara, California, posted revenue of $35.08 billion, up... Read the Full Story |
|
Markets | | |
While Target (NYSE: TGT) has been a bellwether of retail sector health in recent years, it is not today. The company’s lackluster results are due to its operational quality and lack of relevance in an environment where consumers are budget-conscious. Results from other retailers, including... Read the Full Story |
|
From Our Partners | | A Historic Gold Announcement Is About to Rock Wall Street?
For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains. | | Click here to get Garrett’s Top Four picks now. |
|
Stocks | | | One of Asia’s richest men, Indian tycoon Gautam Adani, is again in the spotlight. His companies’ stocks plunged up to 20% in value Thursday after he was indicted by U.S. prosecutors on charges that he duped investors in a massive solar energy project in India by concealing that it was being facilita... Read the Full Story |
|
Markets | | | Just a few weeks ago, the path ahead for the Federal Reserve looked straightforward: With inflation cooling and the job market slowing, the Fed appeared on track to steadily cut interest rates.In September, its officials predicted that they would reduce their benchmark rate four times next year, on ... Read the Full Story |
|
Markets | | |
Williams-Sonoma (NYSE: WSM) offers everything an investor could want and more, making it a stock worthy of buy-and-hold status. Its quality is centered on the brand and operations, which CEO Laura Alber stewards. The results of her tenure include growth, operational improvement, market share gain,... Read the Full Story |
|
Markets | | | Nvidia has once again turned out quarterly results that exceeded Wall Street's forecasts. The company has seen soaring demand for its semiconductors, which are used to power artificial intelligence applications. Revenue nearly doubled in the latest quarter from the same period a year earlier, Nvidia... Read the Full Story |
|
Stocks | | |
The ultimate goal of a business is to generate cash for its shareholders. Investors often consider net income the “bottom line” of a business, indicating how much profit it makes. Net income equals revenue minus expenses. However, some types of revenue and some types of expenses don&rs... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. | | View Today's Stock Pick |
|
